EDAP TMS SA (FOCL)

Currency in USD
5.425
+0.075(+1.40%)
Closed·
5.4250.000(0.00%)
·
Advertisement
Trading near 52-week High
FOCL is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
5.3005.480
52 wk Range
1.2105.480
Key Statistics
Prev. Close
5.35
Open
5.44
Day's Range
5.3-5.48
52 wk Range
1.21-5.48
Volume
22.77K
Average Volume (3m)
37.76K
1-Year Change
253.6506%
Book Value / Share
0.27
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
FOCL Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.875
Upside
+26.73%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in overbought territory

EDAP TMS SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.875
(+26.73% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Lucid Capital Markets
Buy10.00+84.33%-New Coverage22/06/2026
H.C. Wainwright
Buy10.00+84.33%14.00Maintain10/04/2026
Piper Sandler
Hold2.50-53.92%1.50Maintain20/01/2026
Jefferies
Hold2.00-63.13%1.80Maintain06/11/2025

EDAP TMS SA Earnings Call Summary for Q1/2026

  • Q1 2026 revenue hit $15.42M, beating forecast by 4.4% with 25% YoY growth driven by 78% surge in HIFU segment sales.
  • EPS loss of $0.2077 missed estimates of $0.19; gross margin improved to 45.7% from 42.0% YoY despite $7.4M operating loss.
  • Stock surged 14.88% pre-market on revenue beat, trading at $4.17 with 87% one-year gain, though analysts flag overvaluation concerns.
  • CEO Oczachowski emphasized HIFU platform expansion in U.S. and international markets as core strategic focus for growth.
  • Company expects continued revenue growth but projects ongoing EPS losses; profitability not anticipated this year per analyst consensus.
Last Updated: 13/05/2026, 17:18
Read Full Transcript

Earnings

Latest Release
07/05/2026
EPS / Forecast
-0.21 / -0.19
Revenue / Forecast
15.42M / 14.77M
EPS Revisions
Last 90 days

EDAP (FOCL) Income Statement & Profits

Compare FOCL to Peers and Sector

Metrics to compare
FOCL
Peers
Sector
Relationship
P/E Ratio
−6.6x−4.0x−0.4x
PEG Ratio
0.20−0.010.00
Price/Book
20.1x2.3x2.6x
Price / LTM Sales
2.7x2.5x3.0x
Upside (Analyst Target)
35.5%21.0%49.7%
Fair Value Upside
Unlock1.0%7.3%Unlock

EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
605.53K1.62%3.19M
Other Institutional Investors
14.36M38.32%75.63M
Public Companies & Retail Investors
22.51M60.06%118.53M
Total
37.48M100.00%197.34M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Soleus Capital Management, L.P.19.50%7,309,25438,483
Morgan Stanley8.93%3,345,28017,613

People Also Watch

6.250
CPIX
-0.64%
16.34
ANIK
+2.96%
15.740
CHCI
-1.07%
34.48
THRM
0.00%
1.340
AWRE
-1.47%

FAQ

What Is the EDAP (NASDAQ: FOCL) Share Price Today?

The EDAP stock price today is 5.425 USD.

What Stock Exchange Does EDAP (FOCL) Trade On?

EDAP is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for EDAP?

The stock symbol (also called a 'ticker') for EDAP is "FOCL."

What Is the Current EDAP Market Capitalisation?

As of today, EDAP (NASDAQ: FOCL) market cap is 200.530M USD.

What Is EDAP's (FOCL) Earnings Per Share (TTM)?

The EDAP EPS is currently -0.824 (Trailing Twelve Months).

When Is the Next EDAP Earnings Date?

EDAP's next earnings report will be released on 26/08/2026.

Is FOCL a Buy or Sell From a Technical Analyst Perspective?

Based on today's EDAP moving averages and other technical indicators, the daily buy/sell signal for FOCL stock is Strong Buy.

How Many Times Has EDAP Stock Split?

EDAP has split 0 times. (See the FOCL stock split history page for full effective split date and price information.)

How Many Employees Does EDAP Have?

EDAP has 289 employees, based on their latest Companies House report.

What is the current trading status of EDAP (NASDAQ: FOCL)?

As of 08/07/2026, EDAP (FOCL) is trading at a share price of 5.425 USD, with a previous close of 5.350 USD. The stock has fluctuated within a day range of 5.300 USD to 5.480 USD, while its 52-week range spans from 1.210 USD to 5.480 USD.

What Is EDAP (FOCL) Price Target According to Analysts?

The average 12-month price target for EDAP is 6.875 USD, with a high estimate of 10 USD and a low estimate of 3 USD. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +26.73% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.